(178 days)
The Medcomp® Split Cath® III is indicated for use in attaining long term vascular access for Hemodialysis and Apheresis. It may be inserted percutaneously and is primarily placed in the internal jugular vein. Alternate insertion sites include the subclavian vein. Catheters greater than 40cm are intended for femoral vein insertion.
The Medcomp® Split Cath® III is indicated for use in attaining long term vascular access for Hemodialysis and Apheresis in the adult patient. It may be inserted percutaneously and is primarily placed in the internal jugular vein. Alternate insertion sites include the subclavian vein and inferior vena cava as required. Catheters greater than 40cm are intended for femoral vein or inferior vena cava insertion. Translumbar insertion via inferior vena cava is indicated when all other access sites are identified as non-viable.
- 14 French, double "D" Jumen design with cuff for long-term implant.
- Variety of lumen lengths from 20cm to 55cm.
- Soft radiopaque polyurethane material
- Lumen is connected to the extension via a soft pliable hub with a suture wing
- Red and blue clamps and red and blue sleeves are provided on the extension tube to prevent air/fluid communications
- The hub contains the device name and French size, clamp I.D. Rings are printed with the priming volume.
The provided document is a 510(k) Summary for the Medcomp® Split Cath® III, a hemodialysis catheter. It focuses on demonstrating substantial equivalence to predicate devices rather than providing detailed acceptance criteria and a study design with performance metrics for a novel AI device. Therefore, much of the requested information (like acceptance criteria for AI performance, sample sizes for training/test sets in an AI context, expert qualifications, adjudication methods, MRMC studies, standalone performance, and ground truth types for AI) is not applicable or present in this document.
The document details safety and performance tests for the physical medical device itself, not for an AI algorithm.
However, I can extract information regarding the device's functional performance and the tests conducted.
1. Table of Acceptance Criteria and Reported Device Performance
Since this is a submission for substantial equivalence of a physical medical device, not an AI product, the "acceptance criteria" are implied by meeting the requirements of the standards and demonstrating performance comparable to predicate devices. The document does not explicitly list numerical acceptance criteria for each test, but it states that "Subject product testing has yielded acceptable safety and performance outcomes."
| Acceptance Criteria (Implied by Standards) | Reported Device Performance |
|---|---|
| Biocompatibility requirements | Met ISO 10993 Part 1 |
| Sterile Single Use-Intravascular Catheters, General Requirements | Met ISO 10555-1: 1997 |
| Sterile Single Use-Intravascular Catheters, Central Venous Catheters | Met ISO 10555-3: 1997 |
| Conical Fittings with a 6% (Luer) Taper for Syringes, Needles, and Certain Other Medical Equipment - Part 2: Lock Fittings | Met ISO 594-2 |
| Air Leakage | Acceptable outcomes |
| Liquid Leakage | Acceptable outcomes |
| Priming Volume | Acceptable outcomes |
| Flow vs. Pressure | Acceptable outcomes |
| Force at Break / Tensile Strength | Acceptable outcomes |
| Recirculation | Acceptable outcomes |
| Chemical Exposure | Acceptable outcomes |
| Accelerated Aging | Acceptable outcomes |
2. Sample size used for the test set and the data provenance
The document does not specify sample sizes (e.g., number of catheters tested) for the performance tests. It refers to "Subject product testing" but does not give numerical details. The data provenance is internal to Medcomp, a US-based company. The tests are prospective tests on manufactured devices, not retrospective clinical data analysis.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This is not applicable as the document describes physical device testing against engineering standards, not expert-based ground truth for an AI algorithm. The "ground truth" is defined by the international standards themselves.
4. Adjudication method for the test set
Not applicable, as it's not an AI study requiring adjudication of expert opinions. The tests are objective measurements against established engineering standards.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a 510(k) for a physical medical device, not an AI system.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Not applicable. This is a 510(k) for a physical medical device designed for human use, not an AI algorithm.
7. The type of ground truth used
For the physical device performance, the "ground truth" is established by adherence to recognized international standards and engineering specifications (e.g., ISO 10555-1, ISO 10555-3, ISO 594-2, ISO 10993-1).
8. The sample size for the training set
Not applicable. There is no AI training set involved.
9. How the ground truth for the training set was established
Not applicable. There is no AI training set involved.
§ 876.5540 Blood access device and accessories.
(a)
Identification. A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device.
(2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle).
(3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).
(b)
Classification. (1) Class II (special controls) for the implanted blood access device. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.
(ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated.
(B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided.
(C) Priming volumes must be established.
(D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use.
(E) Air leakage testing and liquid leakage testing must be conducted.
(F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage.
(G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern.
(H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established.
(iii) Performance data must demonstrate the sterility of the device.
(iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing.
(v) Labeling of implanted blood access devices for hemodialysis must include the following:
(A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated.
(B) Labeling must specify the forward and reverse recirculation rates.
(C) Labeling must provide the arterial and venous priming volumes.
(D) Labeling must specify an expiration date.
(E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device.
(F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient.
(G) Labeling must include a patient implant card.
(H) The labeling must contain comprehensive instructions for the following:
(
1 ) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;(
2 ) Proper care and maintenance of the device and device exit site;(
3 ) Removal of the device;(
4 ) Anticoagulation;(
5 ) Management of obstruction and thrombus formation; and(
6 ) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following:
(A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port.
(B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following:
(A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied.
(B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties.
(C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens.
(D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness.
(viii) The following must be included for A-V shunt cannulae (with vessel tips):
(A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply.
(B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(2) Class II (performance standards) for the nonimplanted blood access device.
(3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section.
(4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.